Virginia Mason Medical Centre Benaroya Research Institute-2
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Echevarria, Franklin
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
SISTER, NCT05948566: Strategy for Improving Stroke Treatment Response

Recruiting
2
300
US
TS23
Translational Sciences, Inc., University of Cincinnati, National Institute of Neurological Disorders and Stroke (NINDS), Medical University of South Carolina, University of Arizona
Ischemic Stroke
07/27
12/27
CREST-2, NCT02089217: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

Active, not recruiting
N/A
2486
Europe, Canada, US, RoW
Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS
Thomas G. Brott, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Carotid Stenosis
02/26
02/26
Conte, William
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
LeVine, Nicholas
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30

Download Options